{
  "ticker": "GLO",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972385",
  "id": "02972385",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250724",
  "time": "1458",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m3gjp5cl5l59.pdf",
  "summary": "### Fund Update Summary (June 2025)  \n\n#### **Key Portfolio Data**  \n- **Top 5 Holdings**: Merck & Co. (2.9%), Bank of Nova Scotia (2.9%), Sanofi (2.7%), Rheinmetall (2.5%), Standard Chartered (2.4%).  \n- **Sector Allocation**: Financials (18.4%), Industrials (13.6%), IT (13.6%), Health Care (8.5%).  \n- **Regional Allocation**: North America (53.9%), Europe ex-UK (19.1%), UK (7.7%), Asia ex-Japan (5.4%).  \n\n#### **Performance (Net of Fees, to 30 June 2025)**  \n- **1-Year Return**: +21.79% (vs. Benchmark +18.48%).  \n- **3-Year p.a.**: +15.58% (vs. Benchmark +20.22%).  \n- **Underperformance**: Lagged benchmark in Q2 (+1.7% vs. MSCI World +5.9%) due to value stocks\u2019 reversal.  \n\n#### **Notable Stock Commentary**  \n- **Outperformers**: BAE Systems (defense spending upside), Microchip Tech (semiconductor recovery).  \n- **Detractors**: Halliburton (oil capex slowdown), Merck & Co. (China vaccine sales decline).  \n\n#### **Market Outlook**  \n- **Macro Risks**: Trade friction, narrow AI-driven market leadership, uneven global growth.  \n- **Opportunities**: Fiscal stimulus, rate cuts, and cyclical dislocations may benefit value strategies.  \n\n**No material capital markets actions (e.g., raising, corporate action) identified.**  \n*Note: Benchmark = MSCI World Net TR (AUD). Management fee: 0.99%.*",
  "usage": {
    "prompt_tokens": 2561,
    "completion_tokens": 378,
    "total_tokens": 2939,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T06:03:05.378284"
}